For example, previous studies highlighted the potential benefits of combining CSF1R inhibitors with immune checkpoint blockade preclinically; however, most clinical trials testing this combination have yielded insufficient anti-tumor efficacy [19–26]. The gene discussed is CSF1R; the disease is neoplasm.